Oligasis Inc.
This article was originally published in Start Up
Executive Summary
Current technologies for increasing the biocompatibility of engineered antibodies, protein fragments, and other biological agents, such as PEGylation and various protein chaperones, have achieved a maximum half-life extension of about 60 to 80 hours. Frequent dose regimens remain necessary, holding back many potential products. Oligasis Inc. is developing a zwitterionic polymer structure as a conjugate it believes should increase any biological drug's half-life by as much four-fold over the current state of the art.